Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Astellas licenses Theravance gram-positive antibiotic; deal terminated

Executive Summary

To continue building its pipeline of infectious disease therapeutics, Astellas Pharma (created from the merger of Yamanouchi and Fujisawa earlier this year) has licensed worldwide rights (excluding Japan) to develop and commercialize Theravance's telavancin lipoglycopeptide injectable antibiotic for gram-positive infections such as drug-resistant Staphylococcus aureus strains.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies